Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies
Recruiting now · Phase 1
Conditions studied: Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS
In brief
This Phase I dose-escalation trial is designed to evaluate the safety of administering rapidly -generated tumor multi-antigen associated -specific cytotoxic T lymphocytes, to HSCT recipients with high risk AML and MDS.
Key facts
- Study ID
- NCT02203903
- Run by
- Catherine Bollard
- People needed
- 50
- Starts
- 2015-01-01
- Expected to finish
- 2027-06-28
- Last updated by the study team
- 2025-05-31
Who can join
Age: 1 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Childrens National Medical Center — Washington D.C., District of Columbia, United States (enrolling)
- Tania Jain, MD — Baltimore, Maryland, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.